Skip to content

Comparison of hypofractionated helical tomotherapy (TOMO) concurrent chemoradiation therapy versus conventional intensity-modulated radiation therapy concurrent chemoradiation therapy for the inoperable stage III non-small cell lung cancer: a prospective, randomized, multicenter controlled trial

Comparison of hypofractionated helical tomotherapy (TOMO) concurrent chemoradiation therapy versus conventional intensity-modulated radiation therapy concurrent chemoradiation therapy for the inoperable stage III non-small cell lung cancer: a prospective, randomized, multicenter controlled trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017367
Enrollment
Unknown
Registered
2018-07-26
Start date
2018-07-19
Completion date
Unknown
Last updated
2018-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

III non-small cell lung cancer

Interventions

Group 1:TOMO

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed by pathology or cytology as non-small cell lung cancer; 2. Clinically diagnosed as IIIB or IIIC by imaging examination included chest enhanced CT, cranial MRI and PET-CT; 3. Surgical treatment is not available: the same center must be consulted by two senior thoracic surgeons. If the two physicians have different opinions, then the third senior thoracic surgeon should be consulted; 4. Aged 18-75 years; 5. KPS score > 70 points or PS score 0-2 points; 6. The patient was initially treated, and no other anti-tumor treatment was received before enrollment. There was no pleural invasion and pleural effusion, respiratory function compensation and heart, liver, kidney and other organs; 7. Biopsy pathological detection of genes should be tested in lung adenocarcinoma patients before enrollment, including EGFR, ALK receptor negative; 8. No history of chest radiotherapy; 9. Patients could understand the situation of this study and have signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. have malignant tumors of other organs at the same time or 1.5 times the upper limit of normal (ULN); 2.5 times as much aspartate aminotransferase (AST), alanine aminotransferase (ALT) > ULN; serum creatinine > 1.5 times the upper limit of normal, And creatinine clearance < 60 ml / min; 8. without legal capacity or legal capacity is restricted; 9. has other experimental drugs at the same time or is participating in other clinical trials; 10. with any other circumstances that the investigators consider to be unsuitable for participation in the trial.

Design outcomes

Primary

MeasureTime frame
3 year overall survival rate;

Secondary

MeasureTime frame
local control rate;progression free survival;

Countries

China

Contacts

Public ContactHe Jian

Zhongshan Hospital, Fudan University

hejian62@163.com+86 13386057161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026